AI Science Tracker

Tencent AI for Life Sciences Lab

3 discoveries from 2025 to 2026

Discoveries

ERTransformer-generated TCR candidates activate T cells in defined receptor contexts

ERTransformer generated epitope-conditioned TCR β-chain CDR3 candidates. Flow-cytometry experiments found selected artificial TCRs induced activation comparable to or greater than natural controls in defined TCR/pMHC contexts. This represents the September 2026 journal report; an ERTransformer precursor was posted October 20, 2023. The earlier report does not establish that these journal wet-lab results were already public.

Technology: ERTransformer; EpitopeBERT; ReceptorBERT

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Selected generated candidates tested for T-cell activation by flow cytometry.
  • Still unknown: Full experimental methods and supplements not assessed: publisher rendering exposed abstract and metadata. General specificity, safety and clinical outcomes are not established by this review.
  • AI role: Generates TCR β-chain CDR3 candidates conditioned on epitopes.

Evidence sources: https://link.springer.com/article/10.1186/s13059-026-04266-w · https://www.biorxiv.org/content/10.1101/2023.10.18.562845v1

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

ORI engineers active lysozymes, heat-tolerant chitinases and dual-activity enzymes

Tencent researchers used ontology-conditioned generation and experimental feedback to engineer enzymes. In the reported assays, lysozyme TX-RL15 exceeded the earlier TX-L6 design by 66-fold and hen egg-white lysozyme by over two orders of magnitude. Chitinase TX-SC2 retained activity after incubation at 85 °C; selected proteins combined lysozyme and chitinase activity. These are bounded biochemical results. The date represents initial journal publication; the version of record followed on May 7, 2026.

Technology: ORI; protein generation model (PGM); unified sequence model (USM)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Expression, enzyme-activity and heat-treatment assays on selected generated proteins.
  • Still unknown: Separate supplements and independent replication not assessed. Assay-specific advantages do not establish industrial or clinical outcomes.
  • AI role: Ontology-conditioned generation and reinforcement learning from experimental feedback.

Evidence sources: https://www.nature.com/articles/s41467-026-69855-6?error=cookies_not_supported

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

tFold designs binding antibodies against four defined antigens

Tencent researchers generated antibodies against influenza hemagglutinin, PD-1, PD-L1 and SARS-CoV-2 RBD, followed by phage-display screening and SPR characterization. Anti-SC2RBD-H330 showed neutralization IC50 of 0.42 nM. Screening remained extensive, and some confident epitope predictions failed competition tests. The date represents initial journal publication, preceding the January 19, 2026 version of record; a tFold precursor was posted February 8, 2024.

Technology: tFold System; tFold-Ab; tFold-Ag; AlphaFold-Multimer

Family AlphaFold: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Binding and competition assays on generated antibodies; RBD-antibody neutralization.
  • Still unknown: Separate supplements and independent replication not assessed. First-public dates of individual journal experiments were not established by precursor version comparison.
  • AI role: Generates CDR sequences and predicts complexes for structure-guided filtering.

Evidence sources: https://www.nature.com/articles/s41467-025-67361-9?error=cookies_not_supported · https://www.biorxiv.org/content/10.1101/2024.02.05.578892v1

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.